Elucidating isoniazid resistance using molecular modeling

Journal of Chemical Information and Modeling

Volumn 49, Issue 1, 2009, Pages 97-107

  Wahab, Habibah A ^a,b   Choong, Yee Siew ^b,c   Ibrahim, Pazilah ^b   Sadikun, Amirin ^b   Scior, Thomas ^d  

^a SCHOOL OF PHYSICS   (Malaysia)

^b SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^c INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

^d BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; FREE ENERGY; HYDROGEN BONDS; MOLECULAR DYNAMICS; MOLECULAR MODELING; MOLECULES; PROTEINS;

ACYL CARRIER PROTEINS; BINDING AFFINITIES; FREE-ENERGY CALCULATIONS; ISONIAZID RESISTANCE; MOLECULAR DOCKING; MOLECULAR DYNAMICS SIMULATIONS; MYCOBACTERIUM TUBERCULOSIS; WILD-TYPE PROTEINS;

HYDRAZINE;

BACTERIAL PROTEIN; DRUG DERIVATIVE; INHA PROTEIN, MYCOBACTERIUM; ISONIAZID; ISONICOTINYL NAD; ISONICOTINYL-NAD; LIGAND; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXIDOREDUCTASE; WATER;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETICS; INFORMATION SCIENCE; METABOLISM; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PROTEIN CONFORMATION; THERMODYNAMICS;

BACTERIAL PROTEINS; CATALYTIC DOMAIN; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; INFORMATICS; ISONIAZID; LIGANDS; MODELS, MOLECULAR; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NAD; OXIDOREDUCTASES; PROTEIN CONFORMATION; THERMODYNAMICS; WATER;

EID: 61949446364     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci8001342     Document Type: Article

References (83)

1. Gomez, J. E.; McKinney, J. D. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004, 84, 29-44.
2. Bass, J. B.; Farer, L. S.; Hopewell, P. C.; O'Brien, R.; Jacobs, R. F.; Ruben, F.; Snider, D. E.; Thornton, G. Treatment of tuberculosis and tuberculosis Infection in adults and children. Am. J. Respir. Crit. Care Med. 1994, 149, 1359-1374.
3. Iyawoo, K. Tuberculosis in Malaysia: problems and prospect of treatment and control. Tuberculosis 2004, 84, 4-7.
4. Yam, W. C.; Tam, C. M.; Leung, C. C.; Tong, H. L.; Chan, K. H.; Leung, E. T.; Wong, K. C.; Yew, W. W.; Seto, W. H.; Yuen, K. Y.; Ho, P. L. Direct detection of rifampin-resistant Mycobacterium tuberculosis in respiratory specimens by PCR-DNA sequencing. J. Clin. Microbiol. 2004, 42, 4438-4443.
5. Pablos-Mendez, A.; Gowda, D. K.; Frieden, T. R. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull. World Health Org. 2002, 80, 489-495.
6. Gandhi, N. R.; Moll, A.; Sturm, A. W.; Pawinski, R.; Govender, T.; Lalloo, U.; Zeiler, K.; Andrews, J.; Friedland, G. Extensively drugresistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368, 1575-1580.
7. Shah, N. S.; Wright, A.; Bai, G. H.; Barrera, L.; Boulahbal, F.; Martin-Casabona, N.; Drobniewski, F.; Gilpin, C.; Havelková, M.; Lepe, R.; Lumb, R.; Metchock, B.; Portaels, F.; Rodrigues, M. F.; Rüsch-Gerdes, S.; Van Deun, A.; Vincent, V.; Laserson, K.; Wells, C.; Cegielski, J. P. Worldwide emergence of extensively drug-resistant tuberculosis. Emerging Infect. Dis. 2007, 13, 380-387.
8. Migliori, G. B.; Loddenkemper, R.; Blasi, F.; Raviglione, M. C. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic. Eur. Respir. J. 2007, 29, 423-427.
9. Koch-Weser, D.; Ebert, R. H.; Barclay, W. R.; Lee, V. S. Studies on the metabolic significance of acid-fastness of tubercle bacilli. J. Lab. Clin. Med. 1953, 42, 828-829.
10. Winder, F. G.; Collins, P. B. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J. Gen. Microbiol. 1970, 63, 41-48.
11. Takayama, K.; Wang, L.; David, H. L. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of. Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1972, 2, 29-35.
12. Davidson, L. A.; Takayama, K. Isoniazid inhibition of the synthesis of monounsaturated long-chain fatty acids in Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 1979, 16, 104-105.
13. Kikuchi, S.; Takeuchi, T.; Yasui, M.; Kusaka, T.; Kolattukudy, P. E. A very long-chain fatty-acid elongation system in Mycobacterium avium and a possible mode of action of isoniazid on the system. Agric. Biol. Chem. 1989, 53, 1689-1698.
14. Quemard, A.; Lacave, C.; Laneelle, G. Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium Aurum. Antimicrob. Agents Chemother. 1991, 35, 1035-1039.
15. Banerjee, A.; Dubnau, E.; Quemard, A.; Balasubramanian, V.; Um, K. S.; Wilson, T.; Collins, D.; de Lisle, G.; Jacobs, W. R., Jr. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994, 263, 227-230.
16. Telenti, A.; Honore, N.; Bernasconi, C.; March, J.; Ortega, A.; Heym, B.; Takiff, H. E.; Cole, S. T. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J. Clin. Microbiol. 1997, 35, 719-723.
17. Wang, J. Y.; Burger, R. M.; Drlica, K. Role of Superoxide in catalase-peroxidase-mediated isoniazid action against mycobacteria. Antimicrob. Agents Chemother. 1998, 42, 709-711.
18. Fang, Z.; Doig, C.; Rayner, A.; Kenna, D. T.; Watt, B.; Forbes, K. J. Molecular evidence for heterogeneity of the multiple-drug-resistant Mycobacterium tuberculosis population in Scotland (1990 to 1997). J. Clin. Microbiol. 1999, 37, 998-1003.
19. Vilcheze, C.; Morbidoni, H. R.; Weisbrod, T. R.; Iwamoto, H.; Kuo, M.; Sacchettini, J. C.; Jacobs, W. R., Jr. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J. Bacteriol. 2000, 182, 4059-4067.
20. Middlebrook, G. Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. Am. Rev. Tuberc. 1954, 69, 471-472.
21. Winder, F. Catalase and peroxidase in mycobacteria. Possible relationship to the mode of action of isoniazid. Am. Rev. Respir. Dis. 1960, 81, 68-78.
22. Stoeckle, M. Y.; Guan, L.; Riegler, N.; Weitzman, I.; Kreiswirth, B.; Kornblum, J.; Laraque, F.; Riley, L. W. Catalase-peroxidase gene sequences in isoniazid-sensitive and-resistant strains of Mycobacterium tuberculosis from New York City. J. Infect. Dis. 1993, 168, 1063-1065.
23. Heym, B.; Alzari, P. M.; Honore, N.; Cole, S. T. Missense mutations in the catalase-peroxidase genekatG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol. 1995, 15, 235-245.
24. Zhang, Y.; Dhandayuthapani, S.; Deretic, V. Molecular basis for the exquisite sensitivity of Mycobacterium tuberculosis to isoniazid. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 13212-6.
25. Cynamon, M. H.; Zhang, Y.; Harpster, T.; Cheng, S.; DeStefano, M. S. High-dose isoniazid therapy for isoniazid-resistant murine Mycobac-terium tuberculosis infection. Antimicrob. Agents Chemother. 1999, 43, 2922-2924.
26. Lei, B.; Wei, C. J.; Tu, S. C. Action mechanism of antitubercular isoniazid Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor. J. Biol. Chem. 2000, 275, 2520-2526.
27. Zhang, Y.; Heym, B.; Allen, B.; Young, D.; Cole, S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tubercu-losis. Nature 1992, 358, 591-593.
28. Piatek, A. S.; Telenti, A.; Murray, M. R.; El-Hajj, H.; Jacobs, W. R., Jr.; Kramer, F. R.; Alland, D. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob. Agents Chemother. 2000, 44, 103-110.
29. Slayden, R. A.; Barry, C. E. 3rd, The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes. Infect. 2000, 2, 659-669.
30. Torres, M. J.; Criado, A.; Palomares, J. C.; Aznar, J. Use of real-time PCR and fluorimetry for rapid detection of rifampin and isoniazid resistance-associated mutations in Mycobacterium tuberculosis. J. Clin. Microbiol. 2000, 38, 3194-3199.
31. Morris, S.; Bai, G. H.; Suffys, P.; Portillo-Gomez, L.; Fairchok, M.; Rouse, D. Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. J. Infect. Dis. 1995, 171, 954-960.
32. Lee, A. S.; Lim, I. H.; Tang, L. L.; Telenti, A.; Wong, S. Y. Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob. Agents Chemother. 1999, 43, 2087-2089.
33. Kiepiela, P.; Bishop, K. S.; Smith, A. N.; Roux, L.; York, D. F. Genomic mutations in the katGinhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuber. Lung Dis. 2000, 80, 47-56.
34. Musser, J. M.; Kapur, V.; Williams, D. L.; Kreiswirth, B. N.; vanSoolingen, D.; vanEmbden, J. D. A. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and-susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J. Infect. Dis. 1996, 173, 196-202.
35. Rouse, D. A.; Li, Z.; Bai, G. H.; Morris, S. L. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Myco-bacterium tuberculosis. Antimicrob. Agents Chemother. 1995, 39, 2472-2477.
36. Milano, A.; De Rossi, E.; Gusberti, L.; Heym, B.; Marone, P.; Riccardi, G. The katE gene, which encodes the catalase HPII of Mycobacterium avium. Mol. Microbiol. 1996, 19, 113-123.
37. Rozwarski, D. A.; Grant, G. A.; Barton, D. H.; Jacobs, W. R., Jr.; Sacchettini, J. C. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998, 279, 98-102.
38. Miesel, L.; Weisbrod, T. R.; Marcinkeviciene, J. A.; Bittman, R.; Jacobs, W. R., Jr. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J. Bacteriol. 1998, 180, 2459-2467.
39. Basso, L. A.; Zheng, R.; Musser, J. M.; Jacobs, W. R., Jr.; Blanchard, J. S. Mechanisms of isoniazid resistance in Mycobacterium tubercu-losis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 1998, 178, 769-775.
40. Ramaswamy, S.; Musser, J. M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 1998, 79, 3-29.
41. Dessen, A.; Quemard, A.; Blanchard, J. S.; Jacobs, W. R., Jr.; Sacchettini, J. C. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 1995, 267, 1638-1641.
42. Morris, G. M.; Goodsell, D. S.; Huey, R.; Hart, W. E.; Halliday, S.; Belew, R.; Olson, A. J. User Guide: AutoDock Version 3.0.5; The Scripps Research Institute: La Jolla, 2001; p 85.
43. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
44. Case, D. A.; Darden, T. A.; Cheatham, T. E. I.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Wang, B.; Pearlman, D. A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, C.; Caldwell, J. W.; Ross, W. S.; Kollman, P. A. AMBER8; University of California: San Francisco, 2004.
45. Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J.; Kollman, P. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J. Comput. Chem. 2003, 24, 1999-2012.
46. Cheatham, T. E.; Cieplak, P.; Kollman, P. A. A modified version of the Cornell et al. force field with improved sugar pucker phases and helical repeat. J. Biomol. Struct. Dyn. 1999, 16, 845-862.
47. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926-935.
48. Berendsen, H. J. C.; Postma, J. P. M.; Vangunsteren, W. F.; Dinola, A.; Haak, J. R. Molecular-dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81, 3684-3690.
49. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical-integration of Cartesian equations of motion of a system with constraints-molecular-dynamics of n-alkanes. J. Comput. Phvs. 1977, 23, 327-341.
50. Sun, J. P.; Fedorov, A. A.; Lee, S. Y.; Guo, X. L.; Shen, K.; Lawrence, D. S.; Almo, S. C.; Zhang, Z. Y. Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor. J. Biol. Chem. 2003, 278, 12406-12414.
51. Torshin, I. Molecular surface sequence analysis of several E. coli enzymes and implications for existence of casein kinase-2 bacterial predecessor. Front. Biosci. 1999, 4, D394-407.
52. Wang, L. H.; Hingerty, B. E.; Srinivasan, A. R.; Olson, W. K.; Broyde, S. Accurate representation of B-DNA double helical structure with implicit solvent and counterions. Biophys. J. 2002, 83, 382-406.
53. Feig, M.; Karanicolas, J.; Brooks, C. L., III. MMTSB Tool Set; MMTSB NIH Research Resource, The Scripps Research Institute: La Jolla, 2001.
54. Coutinho, P. M.; Dowd, M. K.; Reilly, P. J. Automated docking of monosaccharide substrates and analogues and methyl alpha-acarvi-osinide in the glucoamylase active site. Proteins 1997, 27, 235-248.
55. Sotriffer, C. A.; Flader, W.; Winger, R. H.; Rode, B. M.; Liedl, K. R.; Varga, J. M. Automated docking of ligands to antibodies: methods and applications. Methods 2000, 20, 280-291.
56. Sotriffer, C. A.; Gohlke, H.; Klebe, G. Docking into knowledge-based potential fields: a comparative evaluation of DrugScore. J. Med. Chem. 2002, 45, 1967-1970.
57. Claussen, H.; Buning, C.; Rarey, M.; Lengauer, T. FlexE: efficient molecular docking considering protein structure variations. J. Mol. Biol. 2001, 308, 377-395.
58. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53.
59. Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 1999, 37, 228-241.
60. Vieth, M.; Hirst, J. D.; Kolinski, A.; Brooks, C. L. Assessing energy functions for flexible docking. J. Comput. Chem. 1998, 19, 1612-1622.
61. Ewing, T. J.; Makino, S.; Skillman, A. G.; Kuntz, I. D. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput.-Aided. Mol. Des. 2001, 15, 411-428.
62. Sotriffer, C. A.; Hader, W.; Cooper, A.; Rode, B. M.; Linthicum, D. S.; Liedl, K. R.; Varga, J. M. Ligand binding by antibody IgE Ib4: assessment of binding site preferences using microcalorimetry, docking, and free energy simulations. Biophys. J. 1999, 76, 2966-2977.
63. Denessiouk, K. A.; Johnson, M. S. When fold is not important: a common structural framework for adenine and AMP binding in 12 unrelated protein families. Proteins 2000, 38, 310-326.
64. Schroeder, E. K.; Basso, L. A.; Santos, D. S.; de Souza, O. N. Molecular dynamics simulation studies of the wild-type, I21V, and I16T mutants of isoniazid-resistant Mycobacterium tuberculosis enoyl reductase (InhA) in complex with NADH: toward the understanding of NADH-InhA different affinities. Biophys. J. 2005, 89, 876-884.
65. Chen, Y. Z.; Gu, X. L.; Cao, Z. W. Can an optimization/scoring procedure in ligand-protein docking be employed to probe drug-resistant mutations in proteins. J. Mol. Graphics Modell. 2001, 19, 560-570.
66. Pantano, S.; Alber, F.; Lamba, D.; Carloni, P. NADH interactions with WT- and S94A-acyl carrier protein reductase from Mycobacterium tuberculosis: an ab initio study. Proteins 2002, 47, 62-68.
67. Aqvist, J.; Medina, C.; Samuelsson, J. E. A new method for predicting binding affinity in computer-aided drug design. Protein Eng. 1994, 7, 385-391.
68. Beveridge, D. L.; DiCapua, F. M. Free energy via molecular simulation: applications to chemical and biomolecular systems. Annu. Rev. Biophys. Biophys. Chem. 1989, 18, 431-492.
69. Kollman, P. Free energy calculations: applications to chemical and biochemical phenomena. Chem. Rev. 1993, 93, 2395-2417.
70. Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D. A.; Cheatham, T. E. 3rd., Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res. 2000, 33, 889-897.
71. Bren, U.; Martinek, V.; Florian, J. Free energy simulations of uncatalyzed DNA replication fidelity: Structure and stability of T center dot G and dTTP center dot G terminal DNA mismatches flanked by a single dangling nucleotide. J. Phys. Chem. B 2006, 110, 10557-10566.
72. Dolenc, J.; Baron, R.; Oostenbrink, C.; Koller, J.; van Gunsteren, W. F. Configurational entropy change of netropsin and distamycin upon DNA minor-groove binding. Biophys. J. 2006, 91, 1460-1470.
73. Klauda, J. B.; Brooks, B. R. Sugar binding in lactose permease: Anomeric state of a disaccharide influences binding structure. J. Mol. Biol. 2007, 367, 1523-1534.
74. Trzesniak, D.; Van Der Vegt, N. F. A.; Van Gunsteren, W. F. Analysis of neo-pentane-urea pair potentials of mean force in aqueous urea. Mol. Phys. 2007, 105, 33-39.
75. Böhm, H. J. Prediction of binding constants of protein ligands: a fast method for the prioritization of hits obtained from de novo design or 3D database search programs. J. Comput.-Aided Mol. Des. 1998, 12, 309-323.
76. Zagrovic, B.; van Gunsteren, W. F. Computational analysis of the mechanism and thermodynamics of inhibition of phosphodiesterase 5A by synthetic ligands. J. Chem. Theory Comput. 2007, 3, 301-311.
77. Bren, M.; Florian, J.; Mavri, J.; Bren, U. Do all pieces make a whole? Thiele cumulants and the free energy decomposition. Theor. Chem. Ace. 2007, 117, 535-540.
78. Wang, J.; Dixon, R.; Kollman, P. A. Ranking ligand binding affinities with avidin: a molecular dynamics-based interaction energy study. Proteins 1999, 34, 69-81.
79. Wang, W.; Wang, J.; Kollman, P. A. What determines the van der Waals coefficient beta in the LIE (linear interaction energy) method to estimate binding free energies using molecular dynamics simulations. Proteins 1999, 34, 395-402.
80. 2-symmetric inhibitors of Plasmodium falciparum plasmepsin II: synthesis and theoretical predictions. Bioorg. Med. Chem. 2003, 11, 3723-3733.
81. Florián, J.; Goodman, M. F.; Warshel, A. Computer simulations of protein functions: Searching for the molecular origin of the replication fidelity of DNA polymerases. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 6819-6824.
82. Asi, A. M.; Rahman, N. A.; Merican, A. F. Application of the linear interaction energy method (LIE) to estimate the binding free energy values of Escherichia coli wild-type and mutant arginine repressor C-terminal domain (ArgRc)-L-arginine and ArgRc-L-citrulline protein-ligand complexes. J. Mol. Graphics Modell. 2004, 22, 249-262.
83. Scior, T.; Meneses Morales, I.; Garces Eisele, S. J.; Domeyer, D.; Laufer, S. Antitubercular isoniazid and drug resistance of Mycobac-terium tuberculosis - a review. Arch. Pharm. (Weinheim) 2002, 335, 511-525.